58123-66-3Relevant academic research and scientific papers
PYRIMIDINE DERIVATIVES
-
Page/Page column 101, (2011/04/14)
The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
-
Page/Page column 109-110, (2010/04/28)
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Pteridinone derivatives as PI3-kinases inhibitors
-
Page/Page column 14-15, (2008/12/07)
New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines
Bardelle, Catherine,Coleman, Tanya,Cross, Darren,Davenport, Sara,Kettle, Jason G.,Ko, Eun Jung,Leach, Andrew G.,Mortlock, Andrew,Read, Jon,Roberts, Nicola J.,Robins, Peter,Williams, Emma J.
scheme or table, p. 5717 - 5721 (2009/06/30)
Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilin
